Actively Recruiting
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-04-14
1576
Participants Needed
1
Research Sites
155 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Superficial venous thrombosis (SVT) is very common in clinical practice. What's more, around 15- 20% of SVTs occur in the context of cancer. Today, cancer patients are excluded from therapeutic trials for DVT. There is therefore no high-level evidence-based treatment recommendation for these patients. Recent data suggest that the course of cancer-associated DVT is similar to that of cancer-associated deep vein thrombosis (DVT). However, there are currently few prospective data on the evolution of cancer-associated DVT in relation to the treatment used. Due to the absence of clear recommendations of treatment in case of SVT associated with cancer the investigators will perform a prospective observational study to evaluate the efficacy of different regiment of anticoagulant treatment ordered in clinical practice.
CONDITIONS
Official Title
Prospective Evaluation of the Treatment of Cancer Associated Superficial Venous
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient over 18 years old
- Patient affiliated to a social security scheme
- Patient who understands French
- Superficial venous thrombosis of the lower or upper limbs confirmed by Doppler ultrasound less than one month old
- Active cancer with recent or ongoing treatment within the last 6 months, including detectable tumor disease, hormone therapy, or palliative care
- Received potentially non-curative cancer treatment such as palliative chemotherapy
- Cancer progression showing treatment was not curative, including recurrence after surgery
You will not qualify if you...
- Patients under legal protection
- Patients with concomitant pulmonary embolism
- Patients with proximal or distal deep vein thrombosis
- Patients treated with anticoagulants for other reasons
- Patients with contraindications to anticoagulation such as thrombocytopenia less than 30,000 elements/mm3, active bleeding, or history of severe bleeding
- Patients who refuse to participate in research
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Amiens
Amiens, France, 80480
Actively Recruiting
Research Team
S
Simon SOUDET, Dr
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here